Porfimer sodium

Drug Profile

Porfimer sodium

Alternative Names: CL 184116; Photobarr; Photofrin; Photofrin II; Photofrin PDT; Photofrin Photodynamic Therapy - Axcan Pharma

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QLT
  • Developer Adare Pharmaceuticals; Novelion Therapeutics; Pinnacle Biologics; Roswell Park Cancer Institute; University of Pennsylvania
  • Class Antineoplastics; Hematoporphyrins
  • Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - High-grade oesophageal dysplasia; Cholangiocarcinoma; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bladder cancer; Cervical cancer; Cervical dysplasia; Gastric cancer; High-grade oesophageal dysplasia; Non-small cell lung cancer; Oesophageal cancer
  • Phase III Cholangiocarcinoma
  • Phase II Brain cancer; Mesothelioma

Most Recent Events

  • 26 Jan 2017 Concordia Laboratories initiates enrolment in a phase I trial for Non-small cell lung cancer (Unresectable) in USA and Canada (NCT02916745)
  • 19 Dec 2016 Concordia International terminates the phase III OPUS trial in Cholangiocarcinoma due to slow patient acrual in USA, Canada, Germany, South Korea and Switzerland
  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top